| abstract |
This invention provides methods for determining whether a test compound interacts with the binding between HDM2 and the proteasome. It further provides compounds, pharmaceutical compositions comprising said test compound, and the use of said compounds and compositions, in particular as anti-cancer agent, even more particular for treating cell proliferative disorders in a subject. |